<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> cells generally have a high rate of glycolysis and produce larger quantities of <z:chebi fb="4" ids="24996">lactate</z:chebi> as compared to the surrounding <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Monocarboxylate transporter 4 (MCT4) is one of the proton pumps exchanging the <z:chebi fb="4" ids="24996">lactate</z:chebi> through the plasma membrane </plain></SENT>
<SENT sid="2" pm="."><plain>The prognostic significance of MCT4 expression has not been evaluated in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Surgical specimens from 105 CRC patients were immunohistochemically stained using a polyclonal anti-MCT4 antibody </plain></SENT>
<SENT sid="4" pm="."><plain>The relationships among the MCT4 expression, clinicopathological factors and prognosis were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 53 (50.5%) of the 105 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were determined to have <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> positive for MCT4 expression </plain></SENT>
<SENT sid="6" pm="."><plain>The expression of MCT4 significantly correlated with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size, depth of invasion, lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and TNM staging </plain></SENT>
<SENT sid="7" pm="."><plain>The survival rate of the patients who were positive for MCT4 expression was significantly lower than that of patients with negative MCT4 expression </plain></SENT>
<SENT sid="8" pm="."><plain>Positive MCT4 expression was a significantly poor prognostic factor, as determined by both univariate and multivariate analyses </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, positive MCT4 expression appears to be a useful marker for <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and prognosis in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>